New drug combo aims to tame Tough-to-Treat lymphoma
NCT ID NCT06846463
Summary
This study is testing whether adding an oral drug called zanubrutinib to standard chemotherapy (R-CHOP) works better for people with an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL) who have specific genetic markers. The goal is to see if the combination helps more patients achieve a complete remission and stay cancer-free longer. The trial is for adults with these specific mutations who have had little to no prior treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Virginia Commonwealth University
RECRUITINGRichmond, Virginia, 23298, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.